related documents
- AB0935 Canadian adalimumab post-marketing observational epidemiological study assessing the effectiveness of adalimumab vs non-biologic dmards in psoriatic arthritis (COMPLETE-PSA): 12-month effectiveness data Conferences
- AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study Conferences
- AB1239 The brazilian rheumatology triage: an assessment of the primary healthcare system Conferences
- FRI0217 Diagnostic ascertainment of axial spondyloarthritis in patients presenting with undiagnosed back pain: what is the impact of mri in rheumatological practice? Conferences
- FRI0626 Screening for tuberculosis before tnf inhibitor therapy remains suboptimal: a multi-specialty, real world, nationwide experience in the united states Conferences
- OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab Conferences
- SAT0290 Canadian adalimumab post-marketing observational epidemiological study assessing the effectiveness of adalimumab vs. non-biologic dmards in ankylosing spondylitis (COMPLETE-AS): 12-month effectiveness data Conferences
- SAT0565 Adjusting for the intra-articular placebo effect in knee osteoarthritis therapies Conferences